Study of XL092 in Comb. with Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab…
- Investigator
- Jonathan A Chatzkel
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
High Risk Prostate CA: Less Intense Tx for Low Risk Scores and More Intense Tx for High Risk Scores
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense…
- Investigator
- Jonathan A Chatzkel
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- Male
Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell…
- Investigator
- Jonathan A Chatzkel
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All